





- Most genomic results not actionable
- Many genomic results not informative
- Biological significance and utility lacking
- Genomic test reports highly variable
- Oncologists don't know what to do...about 1/3 of proposed treatments rejected by TAPUR MTB
- Algorithms that inform/direct therapy may help but need proof of clinical utility. What level of evidence required to support adoption?
- Decision algorithm is neither a diagnostic test nor a drug...what is the regulatory oversight?